FT Global Pharma & Biotechnology Conference 2019

Addressing disruption and transformation in pharma

11–12 Nov 2019 | Royal Lancaster, London

This industry-leading event brings together executives from the world’s largest pharmaceutical and biotechnology companies, their health care counterparts, and other key stakeholders across the life sciences value chain to deliberate on key trends and issues that are set to reshape the life sciences sector.

Disruption will continue to take center stage in the life sciences economy for the rest of 2019 and beyond. The sector is constantly evolving all while addressing some significant issues—pricing pressures in many parts of the world, growth in a number of markets, competition from new entrants in the prevention and wellness space, and rise of pricey, potentially curative gene and cell therapies—creating a vacuum for transformation, while generating opportunities and challenges for stakeholders in their journey of care delivery. Executives from across the industry are set to come together at the 37th edition of the FT Global Pharmaceutical and Biotechnology Conference to discuss these trends and more and discuss how to create a successful economic model for life sciences ecosystem of the future.

Visit the FT's conference page for more information on speakers.

25 percent registration discount
(Use code Deloitte25 when registering)

To register for the conference and learn about the speakers, agenda, and topics, visit:

Key issues to be addressed at the conference:

  • Transformation and talent strategies
  • Chief digital officer forum
  • Pharma’s pricing conundrum
  • Alternative funding models for R&D
  • Intellectual property
  • Rewarding innovation and the regulation we need
  • Digital R&D
  • The global competition for investment
  • Innovation on the frontiers or science, medicine and technology
  • What pharma needs to do better at telling its story

Deloitte sessions

Deloitte sessions

11 November 2019 | 1:35 p.m.


  • Camilla Sylvest, EVP, Commercial Strategy and Corporate Affairs, Novo Nordisk
  • Lord Drayson, PhD, CEO, Sensyne Health
  • Eddie Martucci, Co-Founder and CEO, Akili Interactive
  • Hanno Ronte, Partner, Deloitte
  • Dan Vahdat, Founder, Medopad


  • Sarah Neville, Global Pharmaceuticals Editor, Financial Times

11 November 2019 | 3:15 p.m.

Session keynote:

  • Marie-France Tschudin, President, Novartis Pharmaceuticals


  • Mark Howells, Vice President, Global Talent and Development, AstraZeneca
  • Bahija Jallal, CEO, Immunocore
  • Niren Thanky, Consultant & Global Pharmaceutical Practice Leader, Spencer Stuart
  • Hans Trees, Global Head of Pharma Communications and Strategy, Roche


  • Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte

12 November 2019 | 9:20 a.m.


  • Mark Trusheim, Strategic Director, NEWDIGS, MIT Centre for Biomedical Innovation
  • Yvonne Greenstreet, Chief Operating Officer, Alnylam
  • Marc Funk, Chief Executive Officer, Lonza Group
  • Justin McCarthy, Senior Vice President, Patient and Health Impact Group, Pfizer
  • Ilona Torontali, Global Head Access Centre of Excellence for Pricing, HTA, Evidence and Policy, Roche


  • Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte

12 November 2019 | 11:35 a.m.


  • Virginia Acha, Global Regulatory Policy for Europe, Middle East, Africa and Asia, MSD
  • Thomas Senderovitz, Director General, Danish Medicines Agency
  • Arthur Lahr, CEO, Kiadis Pharma
  • Aisling Burnand, CEO, Association of Medical Research Charities (AMRC)


  • Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte

12 November 2019 | 9:05 a.m.

Keynote Address:

Joaquin Duato, Vice Chairmam of the Executive Committee, Johnson & Johnson


Greg Reh, Global Life Sciences & Health Care Industry Leader, Deloitte


Explore our most recent insights:

Tackling digital transformation

Digital transformation in life sciences

Optimizing market access

2019 Global life sciences outlook

Gain the edge in a fast-moving market

Embracing the future of work to unlock R&D productivity

Return on capital performance in life sciences and health care

A bold future for life sciences regulation: Predictions 2025

The next wave of innovation

Digital R&D


Greg Reh

Greg Reh

Deloitte Global Life Sciences & Health Care Leader

Greg is the Deloitte Global Life Sciences & Health Care Industry Leader. In this role, he guides and advises the Life Sciences & Health Care leaders of Deloitte’s global member firm network. He has mo... More

Hanno Ronte

Hanno Ronte

Monitor Deloitte UK

Hanno is a Partner at Monitor Deloitte, in the Deloitte UK’s strategy consultancy business. He has more than 20 years of consulting experience primarily in the Healthcare and Life Sciences sector. Han... More